Phaseline

Companies › Heronova Pharmaceuticals

Heronova Pharmaceuticals: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Oncology, Ophthalmology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DC6001–Phase 1Stargardt DiseaseDec 2026
DC05F01–Phase 1Solid TumorsDec 2027
DC50292A
MTAP inhibitor
MTAPPhase 1Solid Tumor MalignanciesJan 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07417566DC6001Phase 1Stargardt DiseaseOphthalmologyDec 2026
NCT06873555DC05F01Phase 1Solid TumorsOncologyDec 2027
NCT07071090DC50292APhase 1Solid Tumor MalignanciesOncologyJan 2028

Targets

MTAP (1)

Companies with the same targets

Bristol-Myers Squibb Gilead Sciences BeOne Medicines CytosinLab Therapeutics Haisco Pharmaceutical Group Abbisko Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.